Perspective: Innovative medicines require innovative pathways to approval
Stoke CEO and Director Ed Kaye shared his thoughts about the March 2023 FDA approval of omaveloxolone, the first medicine to treat Friedreich’s Ataxia, and what is means for the rare disease community.